CLDI
$0.28-0.02 (-5.57%)
Calidi Biotherapeutics, Inc., a clinical stage immuno-oncology company, develops allogeneic stem cell-based and enveloped virus platforms to potentiate and deliver oncolytic viruses in the United States.
Historical Price
Peer Comparison
Whystock Valuation Model
Fundamentals
Calidi Biotherapeutics, Inc., a clinical stage immuno-oncology company, develops allogeneic stem cell-based and enveloped virus platforms to potentiate and deliver oncolytic viruses in the United States. Its product pipeline comprises CLD-101, which ...
Recent News
Calidi Biotherapeutics to Raise $4.6 Million Through Warrant Exercise Agreement
Calidi Biotherapeutics (CLDI) said Wednesday it has entered into a definitive agreement for the imme
Calidi Biotherapeutics, Inc. (CLDI) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
Calidi Biotherapeutics, Inc. (CLDI) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.